Product Description
Mechanisms of Action: ADRA2 Antagonist,5-HT2 Inverse Agonist,H1 Inverse Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Menopause|Dyssomnias|Parasomnias|Insomnia|Sleep Disorders, Intrinsic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
176003/P05721/MK-8265-007 | P3 |
Terminated |
Sleep Disorders, Intrinsic|Dyssomnias|Insomnia|Parasomnias |
2010-03-10 |
|
JADE | P3 |
Completed |
Insomnia |
2010-02-19 |
|
Jade | P3 |
Completed |
Sleep Disorders, Intrinsic|Insomnia|Parasomnias|Dyssomnias |
2010-02-14 |
|
P05709 | P3 |
Completed |
Dyssomnias|Insomnia |
2009-12-21 |